普通农民家庭出生、收废铁起家，“自行车大佬”王庆太，7.6亿元杀入医药圈！“跨界收购”引爆股价，标的公司连续3日大涨

Core Viewpoint - Wang Qingtai, a well-known entrepreneur in the bicycle industry, is set to become the new actual controller of the struggling pharmaceutical company Duorui Pharmaceutical, marking his entry into the medical capital market [1][5][6]. Company Overview - Duorui Pharmaceutical is currently facing significant operational challenges, with its core product's revenue nearly halved and experiencing its first annual loss since going public [2][11]. - The company reported a revenue of 241 million yuan in 2024, a year-on-year decrease of 28.02%, and a net profit loss of 62.67 million yuan, marking a shift from profit to loss [11][12]. Share Transfer Details - The share transfer agreement involves the transfer of 29.60% of the company's shares at a price of 32.064 yuan per share, totaling approximately 759 million yuan [5]. - After the completion of the share transfer, the new controlling parties will hold up to 53.90% of Duorui Pharmaceutical's shares [5]. Stock Market Reaction - Following the announcement of the change in actual controller, Duorui Pharmaceutical's stock price saw significant fluctuations, with a 12% increase on October 14 and a closing price of 50.43 yuan on October 16, reflecting a 9.82% rise [2][11]. Background of New Controller - Wang Qingtai has a background in the bicycle industry, having built a successful business from scrap metal to leading bicycle manufacturing companies in Hebei [6][7]. - His associates in this acquisition, Cui Zihao and Cao Xiaobing, primarily have backgrounds in the construction industry and lack experience in the pharmaceutical sector [10][12]. Product Performance - Duorui Pharmaceutical's main product, sodium acetate Ringer's injection, has seen a decline in sales from 465 million yuan in 2021 to approximately 120 million yuan in 2024, contributing to the company's overall revenue drop [11][12]. - The company has attempted to mitigate risks by acquiring a 70% stake in Shanghai Jianling Biotechnology, aiming to enter the high-demand peptide raw material market, although this acquisition has not yet contributed positively to its financial performance [12].